Biotech Values

[xavierprivas]

At ASH ARQ531 1/3 durable PR in highest 45 mg cohort (after ~45 wks dosing), strong dose response in C481S
mutation CLL with 5/8 pts with >20% tumor reduction.
Today ARQL reports first PR in C481S mutation CLL at 65mg, 88% tumor reduction.

The next update (my guess is at EHA) should contain a sizeable group of
patients treated at higher doses, specifically patients from
cohort six moving from 45mg to 65mg, as well as six patients on 65mg in cohort seven.

I have no position in ARQL as my bias is ENTA presents better risk/reward.